The Structure of Clinical Translation:Efficiency, Information, and Ethics

A Non-Paternalistic Model of Research Ethics and Oversight: Assessing the Benefits of Prospective Review

(2015) Alex John London   JOURNAL OF LAW MEDICINE & ETHICS

How to increase value and reduce waste when research priorities are set

(2014) Iain Chalmers et al.   LANCET

Response to Sunitinib in Medullary Thyroid Cancer

(2013) Fergal C. Kelleher et al.   ANNALS OF INTERNAL MEDICINE

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

(2013) Alfredo Carrato et al.   JOURNAL OF CLINICAL ONCOLOGY

What is the purpose of medical research?

(2013) The Lancet   LANCET

Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials

(2012) G. A. Freeman et al.   CLINICAL CANCER RESEARCH

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries

(2012) Jonathan Kimmelman   Trials

Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty

(2011) Jonathan Kimmelman et al.   PLOS MEDICINE

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

(2010) L. L. Carr et al.   CLINICAL CANCER RESEARCH

Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials

(2009) Sylvain Mathieu   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with Sunitinib

(2009) M. J. Bugalho et al.   ONCOLOGIST

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

(2008) M. L. Telli et al.   ANNALS OF ONCOLOGY